Condition: Prostatic Neoplasms · Sponsor: The Methodist Hospital Research Institute
The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully impact on the development of metastatic disease and the control of preexisting metastasis.
This description comes directly from the study's public registry record.
Brent Bell, PA-C · 713-394-1105 · bcbell@houstonmethodist.org
Brian Butler, MD · ebutler@houstonmethodist.org
Always discuss trial participation with your own doctor first.
| Houston Methodist | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01913106